[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563027":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":44,"locations":53,"responsibleParty":72,"collaborators":74,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":11,"enrollmentInfo":94,"targetDuration":11,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Washington D.C. Veterans Affairs Medical Center","FED",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Enhertu for HER2 positive metastatic castrate resistant prostate cancer","EXPERIMENTAL",null,[13],"Drug: Enhertu",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Enhertu","This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.",[9],[21,25,29,32,35,38,41],{"name":22,"affiliation":23,"role":24},"Maneesh Jain, MD","Washington DC VA Medical Center","STUDY_CHAIR",{"name":26,"affiliation":27,"role":28},"Eric Knoche, MD","VA St. Louis Healthcare System","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":31,"role":28},"Suman Kambhampati, MD","VA Kansas City",{"name":33,"affiliation":34,"role":28},"Julie Graff, MD","Portland VA Medical Center",{"name":36,"affiliation":37,"role":28},"Bruce Montgomery, MD","VA Puget Sound HCS",{"name":39,"affiliation":40,"role":28},"David Kosoff, MD","Wisconsin VA Medical Center",{"name":42,"affiliation":43,"role":28},"Kerry Schaffer, MD","Vanderbilt University",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Asha Escobar","CONTACT","2027431090","asha.escobar@va.gov",{"name":51,"role":47,"phone":11,"phoneExt":11,"email":52},"Martha Antonio","martha.antonio@va.gov",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Washington DC VAMC","RECRUITING","Washington D.C.","District of Columbia","20422","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-77.03637,38.89511,{"lat":66,"lon":65},[69,71],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":70},"asha.escobar@Va.gov",{"name":22,"role":28,"phone":11,"phoneExt":11,"email":11},{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[75,78,81],{"name":76,"class":77},"Daiichi Sankyo","INDUSTRY",{"name":79,"class":80},"Cancer Research And Biostatistics","UNKNOWN",{"name":82,"class":83},"Institute for Clinical Research","OTHER","100563027","phase-2-castrate-resistant-prostate-cancer-enhertu-therapy-100563027",false,"NCT06610825","Castrate Resistant Prostate Cancer Enhertu Therapy","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma","CaRPET","Inclusion Criteria:\n\n* Pathologically confirmed adenocarcinoma of the prostate\n* Diagnosis of mCRPC\n* Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen\n* Ongoing ADT to maintain serum testosterone levels below 50 ng\u002FdL\n* Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry\n* Life expectancy 6 months\n* ECOG 0 or 1\n* LVEF at least 50%\n* Adequate Blood Clotting function\n* Adequate Organ and Bone Marrow function\n* Adequate Renal function\n* Adequate Hepatic function\n\nExclusion Criteria:\n\n* History of interstitial lung disease or pneumonitis requiring steroids\n* Significant coronary vascular disease\n* Previous exposure to HER2 targeted therapy","MALE","18 Years",{"count":95,"type":96},60,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.",[102,103,104],"Prostate Cancer Metastatic","Prostate Cancer","CRPC",[106,107,17,108,109,110,111],"prostate cancer","metastatic prostate cancer","HER2 positive","Trastuzumab deruxtecan","crpc","phase 2","2026-04-06",{"date":114,"type":115},"2026-04-13","ACTUAL",{"date":117,"type":115},"2025-03-05",{"date":119,"type":96},"2028-10",{"name":5,"class":6},1]